title: Cancer therapies and bone health.
abstract: Cancer patients are at risk for adverse events involving bone. Metastasis of cancer to bone and primary bone tumors can compromise the integrity of bone. Various cancer therapies cause long-term skeletal disorders, particularly bone loss, osteomalacia, and avascular necrosis. Cancer therapies that include chemotherapy, glucocorticoids, hormonal agents, and newer targeted therapies can affect bone in several ways. With the improved effectiveness of cancer treatment, more cancer patients are surviving longer and may experience fractures as a long-term complication of bone loss. Prevention of bone loss through early detection and appropriate use of anti-osteoporosis treatment may decrease bone loss and fractures. This article reviews causative risk factors, mechanisms, and prevention and treatment strategies for cancer therapy-related bone loss in hematologic and specific solid malignancies.
authors.affiliation: Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas M. D. Anderson Cancer Center, 1400 Pressler Street, Houston, TX 77030, USA.
authors.forename: Mimi I
authors.initials: MI
authors.lastname: Hu
authors.forename: Huifang
authors.initials: H
authors.lastname: Lu
authors.forename: Robert F
authors.initials: RF
authors.lastname: Gagel
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D015519:Bone Density / Q000187:drug effects; D001851:Bone Diseases, Metabolic / Q000209:etiology* / Q000378:metabolism; D001859:Bone Neoplasms / Q000378:metabolism / Q000556:secondary; D001862:Bone Resorption / Q000139:chemically induced / Q000209:etiology* / Q000517:prevention & control; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D012307:Risk Factors
chemical_list: D000970:Antineoplastic Agents